Sulzer Medica postpones shareholders meeting:
This article was originally published in Clinica
Executive Summary
Swiss company Sulzer Medica is to postpone an extraordinary shareholders' meeting, planned for December 20, because of the ongoing US litigation over its faulty hip and tibial baseplate products. "We want to know what exactly we are dealing with before presenting the litigation situation to our shareholders and showing them how we will master it," said Max Link, chairman of the board. The company expects to present its strategy for settling the US class action suit in the US at a meeting in the first quarter of 2002. Earlier this month, the company warned it may file for Chapter 11 bankruptcy protection for its US Sulzer Orthopedics division (see Clinica No 984, p 15).
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.